Gold Price Jumps Near 2% Above $4,080 as Middle East Tensions Lift Safe-Haven Demand 
Gold Price Climbs Above $4,130 as Middle East Tensions Boost Safe-Haven Demand 
US Stock Futures Rise as AI Optimism Lifts Tech, 3M Jumps on Strong Earnings 
Trump Announces 100% Tariff on Generic Drug Imports Starting in 2028 
Samsung Cuts U.S. Consumer Electronics Jobs as Headquarters Moves to Texas 
Alphabet Q2 Earnings Beat Estimates as AI Spending, Google Cloud Growth Fuel Outlook 
South Korea Q2 GDP Beats Forecasts as AI Chip Exports Drive Growth 
US-Iran Conflict Escalates as Gulf Attacks Threaten Global Oil Supply 
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth 
Morgan Stanley Downgrades Adobe, Workday as AI Transition Raises Growth Concerns 
Japan Yen Slides Past 163 as Middle East Tensions Lift US Dollar, Oil Prices 
Wistron Opens $700M Texas AI Factory to Build Nvidia Superchips in U.S. 
Super Micro Computer Stock Jumps 20% After Record AI Orders and Margin Surge 
OpenAI Australia Data Center Switches Cooling Strategy After Recycled Water Plan Fails 
Elon Musk Fuels SpaceX-Tesla Merger Speculation After Earnings Call 
Gold Price Surges Above $4,100 as Middle East Tensions Boost Safe-Haven Demand 
Sanofi will be acquiring mRNA developer, Translate Bio, and this was revealed on Monday, Aug. 4. The French pharmaceutical company headquartered in Paris was reported to have offered to buy the US-based company after experiencing setbacks in its attempt to produce its own brand of COVID-19 vaccine.
As per CNBC, Sanofi will purchase all the available shares of the Massachusetts-headquartered mRNA therapeutics company at $38.00 per share. The total equity value is around $3.2 billion, and it will be paid in cash.
An insider who cannot be identified because of the confidentiality of the deal shared that Translate Bio’s board will hold a meeting to discuss the offer. Another source revealed that Sanofi’s executive directors also convened last Sunday to talk about the potential acquisition.
At any rate, it was said that the boards of the two companies gave their approval for the deal. Translate Bio’s chief executive officer, and the firm’s largest shareholder are reportedly backing the takeover offer by Sanofi, and this was confirmed through a joint statement.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Sanofi’s CEO, Paul Hudson, said in a press release. “A fully owned platform allows us to develop additional opportunities in the fast-evolving mRNA space and we will also be able to accelerate our existing partnered programs already under development.”
Hudson added that with Translate Bio, aside from vaccines, Sanofi’s goal is to unravel the potential of messenger ribonucleic acid (mRNA) in other medical fields, including immunology, oncology, and rare diseases.
Prior to this recent acquisition, Sanofi and Translate Bio have actually been working together since 2018, and last year, they teamed up to develop an mRNA-based vaccine for COVID-19. In the third quarter of this year, they are expecting to get provisional results of their Phase I/II clinical trial.
Meanwhile, Reuters reported that shares of Sanofi went up by more than 70% to over $50 in extended trading. The financial terms of the French firm’s offer were not disclosed at this time, and Translate Bio's market value has also soared to around $2.2 billion at the close on Monday.
